降纤酶治疗急性缺血性脑血管病临床疗效.docVIP

降纤酶治疗急性缺血性脑血管病临床疗效[摘要] 目的 分析急性缺血性脑血管病的临床诊断和治疗。 方法 选择2010年1月～2011年12月在本院接受治疗的急性缺血性脑血管病患者330例，随机分成观察组170例和对照组160例，观察组患者给予降纤酶静脉滴注，对照组患者给予复方丹参静脉滴注，观察两组的临床疗效。 结果 观察组患者的总有效率为93.53%，对照组患者的总有效率为81.87%，两组总有效率比较，差异有统计学意义（P ＜ 0.05）；且观察组患者的血浆比黏度、高切值、低切值、纤维蛋白原以及红细胞沉降率等方面指标均明显低于对照组，差异有统计学意义（P ＜ 0.05）。 结论 静脉滴注降纤酶能有效防治凝血和血栓形成，达到治疗急性缺血性脑血管病的目的，值得在临床上推广。 [关键词] 急性缺血性脑血管病；降纤酶；复方丹参；临床疗效 [中图分类号] R743.3 [文献标识码] A [文章编号] 1674-4721（2012）07（c）-0105-02 Clinical efficacy of defibrase in treatment of acute ischemic cerebrovascular disease LUO Weiting People’s Hospital of Xingning City in Guangdong Province, Xingning 514500, China [Abstract] Objective To analyze the clinical diagnosis and treatment of acute ischemic cerebrovascular disease (AICVD). Methods Three hundred and thirty cases of AICVD patients cured in our hospital during January 2010 to December 2011 were selected, and were randomly divided into observation group 170 cases and control group 160 cases, observation group were given intravenous infusion of defibrase, control group were given intravenous infusion of Compound Danshen, the clinical efficacy of two groups were observed. Results The total effective rate of observation group was 93.53%, the total effective rate of control group was 81.87%, there was significant difference between the two groups (P ＜ 0.05); and compared with the control group, the plasma viscosity, high shear value, low shear value, fibrinogen, erythrocyte sedimentation rate of the observation group were lower, there was significant difference (P ＜ 0.05). Conclusion Intravenous infusion of defibrase can effectively prevente clotting and thrombosis, can achieve the purpose of treating AICVD, it is worthy of clinical practice. [Key words] Acute ischemic cerebrovascular disease; Defibrase; Compound Danshen; Clinical efficacy 急性缺血性脑血管病（acute ischemic cerebrovascular disease，AICVD）主要由于一条或多条脑血管缺血导致该供血区局灶性脑功能障碍，出现局灶性神经系统症状体征并持续数分钟至数小时[1]，在临床上比较常见，且多发，其病死率和致残率一直居高不下，病死率仅次于恶性肿瘤[2]。本文重点讨论急性缺血性脑血管病的临床特点及临